Get all your news in one place.

100's of premium titles.
One app.

Start reading

Get all your news in one place.

100's of premium titles. One news app.

Start reading

The Latest Breaking News from Novo Nordisk

2024 Will Be a Good Year for the Pharma Industry: The Kiplinger Letter

Five pharma companies will have sales that exceed $50 billion this year.

Kiplinger

"Faux-zempic" driving hospitalizations

Experts warn against the risks of illegitimately obtained Ozempic and Wegovy

Salon

3 Pharma Stocks for January 2024 Profits

The pharmaceutical industry is thriving, fueled by steady demand for drugs, cost-efficient alternative discoveries, and rapid technological innovations. Hence, fundamentally strong pharma stocks Novo Nordisk (NVO), Eton Pharmaceuticals (ETON), and Pacira BioSciences (PCRX) might be profitable buys now. Read on….

StockNews.com

From analysis to the latest developments in health,
read the most diverse news in one place.

Will weight loss drugs kill the fast food business?

Many firms see the dire forecasts as ‘overblown’ but they know they will have to adapt products to make ‘every bite counts’

The Guardian - UK

Ozempic and Wegovy Show Lower Risk of Suicidal Thoughts

Hold onto your hats, folks, because there's some fascinating news in the world of diabetes and obesity drugs! A recent federal study found that people taki...

Top News

People taking Wegovy and Ozempic have lower risk of suicidal thoughts vs. older drugs, study finds

A new federal study finds that people taking popular diabetes and obesity drugs Ozempic and Wegovy had a lower risk of suicidal thoughts than those taking other medications to treat the same conditions

The Independent UK

Eli Lilly Stock: Buy or Sell?

Eli Lilly's diversified portfolio and high demand for its weight-loss drugs have pushed it to the top of Wall Street's list of top pharma stocks for 2024. Is now the time to buy?

Barchart

Read news from The Economist, FT, and more,
with one subscription

Insulin Now Available for $35 a Month for Many Americans

Insulin price caps from Eli Lilly, Novo Nordisk and Sanofi take effect this month.

Kiplinger

The Guardian view on anti-obesity drugs: treating a disease that modernity made

Editorial: Weight-loss drugs reveal that obesity is not a deep-seated aspect of character but something more contingent

The Guardian - UK

FDA says watch out for fake Ozempic, a diabetes drug used by many for weight loss

Thousands of fake units of the drug have been seized by the FDA, which is working alongside the manufacturer to test the counterfeit products for safety concerns.

WEKU

FDA warns that counterfeit Ozempic is flooding US supply chain

Officials have seized thousands of counterfeit units

The Independent UK

FDA Seizes Thousands of Counterfeit Ozempic Shots for Diabetes

Counterfeit Ozempic diabetes drug seized by FDA, prompting concerns over identity, quality, and safety. Report suspect packages to FDA hotline.

Top News

'I had to set two alarms at night to check my glucose to make sure I wouldn’t die': meet the revolutionary who won't stop until cycling is safer

The UCI banned his technology from races, yet Supersapiens boss Phil Southerland tells Chris Marshall-Bell he is still dead set on changing the sport in the most profound way for decades

Cycling Weekly

Weight loss from Lilly’s Zepbound drug reversed after stopping treatment, according to study

‘They gain back about half the weight they had originally lost over a one-year period of time,’ professor says

The Independent UK

Get all your
news in one place.

100's of premium titles.
One news app.

International Business Times

Chasing Weight Loss Dream, Many In US Seek Ozempic Alternatives

Like many Americans struggling to lose weight, Marissa Montanino felt compelled to try Ozempic or one of the other new so-called "wonder drugs" described as revolutionary in the fight against obesity.

Fortune

Wegovy maker Novo Nordisk could make prices flexible—without cutting them—to persuade more health systems to cover the weight-loss drugs

Weight-loss drug Wegovy faces high demand, limited supply, and tricky health care systems to navigate.

Barchart

3 Buy-Rated Healthcare Dividend Stocks for Income Investors

Looking for analysts' favorite stock picks in a traditionally defensive sector, with solid dividend payments to help boost your returns? Here's a look at three stocks for income investors to consider at current levels.

The Guardian - UK

Revealed: obesity jab maker discussed targeting benefit claimants with UK government

Drug firm Novo Nordisk proposed singling out those most likely to return to work with its weight-loss injection

Get all your
news in one place.

100's of premium titles.
One news app.

Fortune

Germany considers banning Ozempic exports, including to U.S.

Germany exports Ozempic to the EU and the U.S., Karl Broich, president of the German Federal Institute for Drugs and Medical Devices, told Der Spiegel.

Fortune

Scientists have discovered a new benefit to Novo Nordisk’s weight-loss drug Wegovy: It can cut heart-related deaths by 20%, drugmaker reports

Wegovy was found to cut the risk of serious heart events by 20%—Novo Nordisk has now asked the U.S. FDA to reflect the heart benefits in the drug's label.

The Independent UK

Obesity drug Wegovy cut risk of serious heart problems by 20%, study finds

A new large study finds that the popular weight-loss drug Wegovy reduced the risk of serious heart problems by 20% in certain patients

Fortune

Novo Nordisk faces first real test as Eli Lilly wins approval for a weight loss-aiding drug

U.S. regulators signed off on Eli Lilly’s diabetes drug Zepbound, which can also be used to aid weight loss like Wegovy and Ozempic.

The Guardian - UK

AstraZeneca makes big push into weight-loss market with obesity pill deal

UK drugmaker signs agreement with China’s Eccogene to work on an obesity and type 2 diabetes pill

Newsroom.co.nz

How a 'Rule of Two' could remove our barrier to better drug access

We need to address the unnecessary and wasteful Medsafe approval for tried and tested drugs by much bigger regulatory authorities abroad, argues Dr Eric Crampton

Fortune

Novo Nordisk threatens to expand in US in row over EU rules

Novo Nordisk's CEO doesn't like proposed new EU rules that would cut the period for which drugmakers enjoy exclusivity for their products from 10 years to eight years.

1 … 20 21 22 23

People

Lars Fruergaard Jørgensen

18 stories

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.